Prosensa Leads More Biotechs into IPO Parade
By Marie Powers
Wednesday, May 29, 2013
The sizzling initial public offering (IPO) market gained two more biopharma contestants with a third moving carefully toward it, as Prosensa Therapeutics BV filed an F-1 registration statement, Evoke Pharma Inc. filed an S-1 and Oculus Innovative Sciences Inc. disclosed that subsidiary Ruthigen Inc. submitted a confidential draft registration statement to the SEC.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.